Cargando…

SARS-CoV-2 Serologic Assay Needs for the Next Phase of the US COVID-19 Pandemic Response

BACKGROUND: There is a need for validated and standardized severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) quantitative immunoglobulin G (IgG) and neutralization assays that can be used to understand the immunology and pathogenesis of SARS-CoV-2 infection and support the coronavirus dis...

Descripción completa

Detalles Bibliográficos
Autores principales: Gundlapalli, Adi V, Salerno, Reynolds M, Brooks, John T, Averhoff, Francisco, Petersen, Lyle R, McDonald, L Clifford, Iademarco, Michael F
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7717402/
https://www.ncbi.nlm.nih.gov/pubmed/33442555
http://dx.doi.org/10.1093/ofid/ofaa555
_version_ 1783619309364314112
author Gundlapalli, Adi V
Salerno, Reynolds M
Brooks, John T
Averhoff, Francisco
Petersen, Lyle R
McDonald, L Clifford
Iademarco, Michael F
author_facet Gundlapalli, Adi V
Salerno, Reynolds M
Brooks, John T
Averhoff, Francisco
Petersen, Lyle R
McDonald, L Clifford
Iademarco, Michael F
author_sort Gundlapalli, Adi V
collection PubMed
description BACKGROUND: There is a need for validated and standardized severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) quantitative immunoglobulin G (IgG) and neutralization assays that can be used to understand the immunology and pathogenesis of SARS-CoV-2 infection and support the coronavirus disease 2019 (COVID-19) pandemic response. METHODS: Literature searches were conducted to identify English language publications from peer-reviewed journals and preprints from January 2020 through November 6, 2020. Relevant publications were reviewed for mention of IgG or neutralization assays for SARS-CoV-2, or both, and the methods of reporting assay results. RESULTS: Quantitative SARS-CoV-2 IgG results have been reported from a limited number of studies; most studies used in-house laboratory-developed tests in limited settings, and only two semiquantitative tests have received US Food and Drug Administration (FDA) Emergency Use Authorization (EUA). As of November 6, 2020, there is only one SARS-CoV-2 neutralization assay with FDA EUA. Relatively few studies have attempted correlation of quantitative IgG titers with neutralization results to estimate surrogates of protection. The number of individuals tested is small compared with the magnitude of the pandemic, and persons tested are not representative of disproportionately affected populations. Methods of reporting quantitative results are not standardized to enable comparisons and meta-analyses. CONCLUSIONS: Lack of standardized SARS-CoV-2 quantitative IgG and neutralization assays precludes comparison of results from published studies. Interassay and interlaboratory validation and standardization of assays will support efforts to better understand antibody kinetics and longevity of humoral immune responses postillness, surrogates of immune protection, and vaccine immunogenicity and efficacy. Public–private partnerships could facilitate realization of these advances in the United States and worldwide.
format Online
Article
Text
id pubmed-7717402
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-77174022020-12-09 SARS-CoV-2 Serologic Assay Needs for the Next Phase of the US COVID-19 Pandemic Response Gundlapalli, Adi V Salerno, Reynolds M Brooks, John T Averhoff, Francisco Petersen, Lyle R McDonald, L Clifford Iademarco, Michael F Open Forum Infect Dis Review Article BACKGROUND: There is a need for validated and standardized severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) quantitative immunoglobulin G (IgG) and neutralization assays that can be used to understand the immunology and pathogenesis of SARS-CoV-2 infection and support the coronavirus disease 2019 (COVID-19) pandemic response. METHODS: Literature searches were conducted to identify English language publications from peer-reviewed journals and preprints from January 2020 through November 6, 2020. Relevant publications were reviewed for mention of IgG or neutralization assays for SARS-CoV-2, or both, and the methods of reporting assay results. RESULTS: Quantitative SARS-CoV-2 IgG results have been reported from a limited number of studies; most studies used in-house laboratory-developed tests in limited settings, and only two semiquantitative tests have received US Food and Drug Administration (FDA) Emergency Use Authorization (EUA). As of November 6, 2020, there is only one SARS-CoV-2 neutralization assay with FDA EUA. Relatively few studies have attempted correlation of quantitative IgG titers with neutralization results to estimate surrogates of protection. The number of individuals tested is small compared with the magnitude of the pandemic, and persons tested are not representative of disproportionately affected populations. Methods of reporting quantitative results are not standardized to enable comparisons and meta-analyses. CONCLUSIONS: Lack of standardized SARS-CoV-2 quantitative IgG and neutralization assays precludes comparison of results from published studies. Interassay and interlaboratory validation and standardization of assays will support efforts to better understand antibody kinetics and longevity of humoral immune responses postillness, surrogates of immune protection, and vaccine immunogenicity and efficacy. Public–private partnerships could facilitate realization of these advances in the United States and worldwide. Oxford University Press 2020-11-17 /pmc/articles/PMC7717402/ /pubmed/33442555 http://dx.doi.org/10.1093/ofid/ofaa555 Text en Published by Oxford University Press on behalf of Infectious Diseases Society of America 2020. http://www.nationalarchives.gov.uk/doc/open-government-licence/version/2/ This work is written by (a) US Government employee(s) and is in the public domain in the US. This Open Access article contains public sector information licensed under the Open Government Licence v2.0 (http://www.nationalarchives.gov.uk/doc/open-government-licence/version/2/).
spellingShingle Review Article
Gundlapalli, Adi V
Salerno, Reynolds M
Brooks, John T
Averhoff, Francisco
Petersen, Lyle R
McDonald, L Clifford
Iademarco, Michael F
SARS-CoV-2 Serologic Assay Needs for the Next Phase of the US COVID-19 Pandemic Response
title SARS-CoV-2 Serologic Assay Needs for the Next Phase of the US COVID-19 Pandemic Response
title_full SARS-CoV-2 Serologic Assay Needs for the Next Phase of the US COVID-19 Pandemic Response
title_fullStr SARS-CoV-2 Serologic Assay Needs for the Next Phase of the US COVID-19 Pandemic Response
title_full_unstemmed SARS-CoV-2 Serologic Assay Needs for the Next Phase of the US COVID-19 Pandemic Response
title_short SARS-CoV-2 Serologic Assay Needs for the Next Phase of the US COVID-19 Pandemic Response
title_sort sars-cov-2 serologic assay needs for the next phase of the us covid-19 pandemic response
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7717402/
https://www.ncbi.nlm.nih.gov/pubmed/33442555
http://dx.doi.org/10.1093/ofid/ofaa555
work_keys_str_mv AT gundlapalliadiv sarscov2serologicassayneedsforthenextphaseoftheuscovid19pandemicresponse
AT salernoreynoldsm sarscov2serologicassayneedsforthenextphaseoftheuscovid19pandemicresponse
AT brooksjohnt sarscov2serologicassayneedsforthenextphaseoftheuscovid19pandemicresponse
AT averhofffrancisco sarscov2serologicassayneedsforthenextphaseoftheuscovid19pandemicresponse
AT petersenlyler sarscov2serologicassayneedsforthenextphaseoftheuscovid19pandemicresponse
AT mcdonaldlclifford sarscov2serologicassayneedsforthenextphaseoftheuscovid19pandemicresponse
AT iademarcomichaelf sarscov2serologicassayneedsforthenextphaseoftheuscovid19pandemicresponse
AT sarscov2serologicassayneedsforthenextphaseoftheuscovid19pandemicresponse